The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.

AIMS To compare the peripheral vasoconstrictor effects of ergotamine, rizatriptan, and their combination, in normal subjects. METHODS This was a double-blind, four-way, crossover study. Sixteen young male volunteers, selected as responders to the vasoconstrictor effect of 0.5 mg ergotamine i.v., were administered 10 mg oral rizatriptan, 0.25 mg i.v. ergotamine, 10 mg oral rizatriptan+0.25 mg i.v. ergotamine, and placebo. The vasoconstrictor effect on peripheral arteries was measured with strain gauge plethysmography up to 8 h after dosing. The 8 h assessment period was divided into two 4 h intervals to assess the immediate (0-4 h) vs sustained effect (4-8 h) of treatment. RESULTS For the 0-4 h interval, the decreases in peripheral systolic blood pressure gradients were: placebo (-1 mmHg [95% CI: -3, 1])<rizatriptan (-5 mmHg [95% CI: -7, -3])<ergotamine (-15 mmHg [95% CI: -16, -13])=rizatriptan+ergotamine (-15 mmHg [95% CI: -17, -13]). For the 4-8 h interval, the decreases were: placebo (-5 mmHg [95% CI: -8, -3])=rizatriptan (-8 mmHg [95% CI: -11, -5])<ergotamine (-26 mmHg [95% CI: -29, -24])=rizatriptan+ergotamine (-28 mmHg [95% CI: -31, -26]). CONCLUSIONS In normal subjects, rizatriptan 10 mg orally had only a small transient vasoconstrictor effect on peripheral arteries compared with the sustained and more pronounced effect of 0.25 mg i.v. ergotamine. Furthermore, rizatriptan exerted no additional effect on ergotamine-induced constriction of peripheral arteries when the two drugs were given in combination.

[1]  J. Willigers,et al.  Vascular effects of 5‐HT1B/1D‐receptor agonists in patients with migraine headaches , 2000, Clinical pharmacology and therapeutics.

[2]  P. Tfelt-Hansen,et al.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. , 2000, Drugs.

[3]  P R Saxena,et al.  Ergotamine in the acute treatment of migraine: a review and European consensus. , 2000, Brain : a journal of neurology.

[4]  L. Edvinsson,et al.  Contractile 5‐HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry , 1999, British journal of pharmacology.

[5]  N. Mathew,et al.  Cardiovascular Safety of 5Ht1B/1D Agonists—Is There a Cause for Concern? , 1998, Cephalalgia : an international journal of headache.

[6]  M. Ferrari,et al.  Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.

[7]  C. Nordström,et al.  Effects of dihydroergotamine and sumatriptan on isolated human cerebral and peripheral arteries and veins , 1997, Acta anaesthesiologica Scandinavica.

[8]  D. Evans,et al.  Peripheral Vascular Effects and Pharmacokinetics of the Antimigraine Compound, Zolmitriptan, in Combination with Oral Ergotamine in Healthy Volunteers , 1997, Cephalalgia : an international journal of headache.

[9]  F. Oehme.  Goodman and Gilman 's: The pharmacological basis of therapeutics , 1996 .

[10]  G. Renzenbrink,et al.  5-HT receptors mediating contractions of the isolated human coronary artery. , 1993, European journal of pharmacology.

[11]  J. Olesen,et al.  5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences. , 1993, Acta physiologica Scandinavica.

[12]  W. Hillis,et al.  Effect of Subcutaneous Sumatriptan, a Selective 5HT1 Agonist, on the Systemic, Pulmonary, and Coronary Circulation , 1993, Circulation.

[13]  B. Galer,et al.  Myocardial Ischemia Related to Ergot Alkaloids: A Case Report and Literature Review , 1991, Headache.

[14]  W. Feniuk,et al.  Mode of action of the anti-migraine drug sumatriptan. , 1991, Trends in pharmacological sciences.

[15]  M. Perren,et al.  A rational approach to identifying a fundamentally new drug for the treatment of migraine , 1990 .

[16]  W. Feniuk,et al.  5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. , 1989, European journal of pharmacology.

[17]  P. Tfelt-Hansen,et al.  Comparison of Pharmacodynamic Effects and Plasma Levels of Oral and Rectal Ergotamine , 1986, Cephalalgia : an international journal of headache.

[18]  P. Tfelt-Hansen.  The effect of ergotamine on the arterial system in man. , 1986, Acta pharmacologica et toxicologica.

[19]  L. Paalzow,et al.  Intramuscular ergotamine: Plasma levels and dynamic activity , 1985, Clinical pharmacology and therapeutics.

[20]  P. Tfelt-Hansen,et al.  Dose-response curve for the ergotamine-induced decrease of peripheral systolic blood pressure in man. , 2009, Acta pharmacologica et toxicologica.

[21]  J. Olesen,et al.  Arterial response to ergotamine tartrate in abusing and non-abusing migraine patients. , 2009, Acta pharmacologica et toxicologica.

[22]  J. Olesen,et al.  The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. , 2009, Acta pharmacologica et toxicologica.